CAR-T for relapsed or refractory B-ALL after treatment failure
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This trial tests an engineered immune-cell treatment (GC019F CAR-T) for adults with B-cell ALL that has come back or did not respond to prior therapy. If it works, it may help your immune system attack leukemia cells by targeting CD19.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Ages 18 to 70 years
- Your health status is good enough for study visits (ECOG 0 to 2)
- You have CD19 leukemia cells in your blood or bone marrow test
- Your ALL is relapsed or refractory, meaning it didn’t respond or it came back (including after transplant, or special rules for Ph+ cases)
- You have no recent transplant: no stem cell transplant within the last 6 months
- You have enough organ health (kidney, liver, bilirubin) and heart function, and oxygen levels above 92% while breathing room air
- You can get study blood samples and give consent; you agree to follow treatment and safety rules
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a CD19-targeted CAR-T cell therapy (S1904) for people with B-cell acute lymphoblastic leukemia that has come back or not responded to treatment. After CAR-T, some patients may go on to a stem cell transplant. The goal is to see if the CAR-T can lead to remission and who needs a transplant.
This trial tests a new type of immunotherapy called CAR-T cells to help prevent relapse in adults with B-cell acute lymphoblastic leukemia (a blood cancer) who have responded well to standard chemotherapy. The treatment is designed as a consolidation therapy to strengthen remission after initial chemotherapy.
This trial tests a new type of CAR T cell therapy that targets two proteins (CD19 and CD22) found on leukemia cells. It is for children and young adults whose B-ALL has come back multiple times, or who have not responded to other treatments.
This trial is testing a new CAR-T cell therapy (Senl_B19) for children and young adults with B-cell acute lymphoblastic leukemia (B-ALL) that has returned or not responded to treatment. It targets a protein called CD19 on leukemia cells to help your immune system attack the cancer.
This early-phase trial tests a type of immunotherapy called anti-CD19 CAR-T cells. These are specially engineered immune cells that seek out and destroy cancer cells with a marker called CD19 on their surface. It is for people with B-cell cancers (leukemia or lymphoma) that have not responded to or come back after standard treatments.
This trial tests a personalized cell therapy (CAR-T) for people with B-cell acute lymphoblastic leukemia (ALL) that has come back after treatment or is hard to treat. The therapy uses your own immune cells, modified to find and kill leukemia cells.
Hear when a new B-cell Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.